Get started
CNBX Pharmaceuticals Inc.CNBX Pharmaceuticals Inc.CNBX Pharmaceuticals Inc.

CNBX Pharmaceuticals Inc.

No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Seasonals

CNBX fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

CNBX Pharmaceuticals, Inc. is a clinical stage company, which engages in the discovery, development, and commercialization of cannabinoid-based products and technologies for the treatment of cancer. Its products include Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS), and RCC-33, an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC). The company was founded by Eyal Barad on September 15, 2004 and is headquartered in Bethesda, MD.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

CNBX does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company